Pharmaxis announced that Dr. Dieter Hamprecht has been appointed as the Head of Chemistry in the Pharmaxis Drug Discovery team reporting to Department Head Dr. Wolfgang Jarolimek. Dr. Hamprecht was previously the Managing Director of Boehringer Ingelheim's research group in Milan. In addition, Pharmaxis has appointed two new members to its Scientific Advisory Board (SAB). Professor Darren Kelly, PhD, MSc is the Associate Dean (Innovation and Enterprise, MDHS) at The University of Melbourne, the Director of Innovation and Enterprise at the Centre for Eye Research Australia (CERA) and Director of Biomedical Research in the Department of Medicine, St Vincent's Hospital Melbourne. He was CEO of Fibrotech Ltd. which was successfully sold to Shire in 2014 and is now the CEO and Managing Director of OccuRx. Dr. Kathleen Metters, PhD, MS has more than 25 years of experience in the discovery and development of novel therapies for the treatment of serious diseases. She spent 9 years with Merck & Co. including a period as senior vice president and head of Worldwide Basic Research and leading their External Discovery and Preclinical Sciences. She was subsequently appointed President and Chief Executive Officer for Lycera Corp.